The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.
March 08, 2024
This publication discusses the use of Pomalyst (pomalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
July 08, 2024
This publication discusses the use of Revlimid (lenalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
March 20, 2024
The Understanding SARCLISA® (isatuximab-irfc) booklet discusses a novel anti-CD38 monoclonal antibody that is approved for patients with relapsed and…
March 19, 2024
This publication is for myeloma patients in the U.S. who are considering undergoing an autologous stem cell transplant (ASCT).
November 15, 2023
Talvey is indicated for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior lines of therapy.
with support from:
Johnson & Johnson and Pfizer.